ADC 승부수 띄운 삼성에피스홀딩스, 중국에 신약 R&D 센터 설립

Samsung Epics Holdings' establishment of its first global R&D center in Beijing marks a strategic pivot toward ADC (Antibody-Drug Conjugate) technology to strengthen its competitive position in the global biopharmaceutical market. As ADC has become the most sought-after platform technology in modern drug development, this Beijing hub is critical for accelerating Samsung's next-generation pipeline. By leveraging China's world-class research infrastructure and talent ecosystem, the company aims to significantly enhance its drug discovery capabilities.